Evidence map›Paper›PMID 39781738›Full record

ReviewCurrent pharmaceutical design2025

Therapeutic Role of Scutellarein in Neurological Disorders.

Rohit Kumar, Sucharitha Bai, Rahul Shukla, Saba Naqvi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rohit KumarDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Lucknow (UP) 226002, India.
Sucharitha BaiDepartment of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Lucknow (UP) 226002, India.
Rahul ShuklaDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Lucknow (UP) 226002, India.
Saba NaqviDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Lucknow (UP) 226002, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scutellarein, a flavone found in the perennial herb Scutellaria baicalensis, has a wide range of pharmacological actions, such as antioxidant, anti-inflammatory, and neuroprotective. Increasing evidence has emphasized the developing significance of scutellarein in several neurological illnesses, such as Alzheimer's and Parkinson's disease, cerebral ischemia, and neuroblastoma. This review is centered on the molecular processes that underlie the neuroprotective properties of scutellarein in various neurological disorders, as indicated by recent pre-clinical research. Furthermore, it critically examines the potential challenges and advantages of scutellarein inclusion within the range of treatments for neurological disorders.

Indexed as

ApigeninNervous System DiseasesNeuroprotective AgentsAnimalsHumansApigeninNeuroprotective AgentsscutellareinAlzheimer’s diseaseantioxidantcerebral ischemia.neuroblastomaneurodegenerative diseasesParkinson’s diseaseScutellarein

Identifiers

PMID39781738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.